젠큐릭스

229000KOSDAQ의료용품 및 기타 의약 관련제품 제조업

50.5 / 100

Reference Date: 2026-04-13

Financial Score21.5 / 40

News Sentiment15.0 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 30.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Genex develops molecular diagnostic products and services based on liquid biopsy technology, focusing on cancer prognosis and companion diagnostics. Its key products include the breast cancer prognosis test 'GenesWell BCT' and the lung cancer companion diagnostic test 'GenesWell ddEGFR Mutation Test'. The company is also advancing early cancer detection through liquid biopsy products and CTC technology research.

Number of Employees

75people

Average Salary

57.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 19.894.0Point

PBR

3.70Industry Average 1.620.0Point

2.3x industry avg (risky)

ROE

-47.25Industry Average -4.893.5Point

9.7x industry avg (excellent)

Debt Ratio

2.55Industry Average 8.888.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲72.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲23.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -102.0% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 2Neutral 0Negative 0Average Sentiment Score 75

Positive
젠큐릭스, STI 다중진단 플랫폼 서울시 지원사업 선정
젠큐릭스가 성매개감염(STI) 다중진단 플랫폼 개발 및 상용화 과제로 서울시 지원사업에 선정되어 혁신 진단 플랫폼 상용화에 속도를 낼 계획입니다.
Positive
젠큐릭스, 차세대 ‘원스텝 신속 분자진단’ 플랫폼 개발…홈테스트...
젠큐릭스가 호흡기 바이러스 검출을 위한 RT-RPA 및 CRISPR 기술 기반 신속 원스텝 분자진단 시스템 개발을 성공적으로 마무리하며 차세대 분자진단 시장 공략에 나섭니다.

Detailed Momentum

52-week position3.0Point

52w lower range (26%)

Current 2,585Won52-week high 5,87052-week low 1,428

1-month return0.0Point

1m -30.60% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-04-09
Neutral정기주주총회결과2026-03-24
Neutral사업보고서 (2025.12)2026-03-16